SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO • US8342033094

37.72 USD
-1.34 (-3.43%)
At close: Mar 3, 2026
38.25 USD
+0.53 (+1.41%)
After Hours: 3/3/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall SLNO gets a fundamental rating of 6 out of 10. We evaluated SLNO against 520 industry peers in the Biotechnology industry. SLNO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SLNO is valued quite cheap, while showing a decent growth score. This is a good combination! This makes SLNO very considerable for value investing!


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • SLNO had positive earnings in the past year.
  • SLNO had a positive operating cash flow in the past year.
  • SLNO had negative earnings in 4 of the past 5 years.
  • SLNO had negative operating cash flow in 4 of the past 5 years.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of SLNO (3.63%) is better than 89.23% of its industry peers.
  • SLNO has a Return On Equity of 4.55%. This is amongst the best in the industry. SLNO outperforms 90.00% of its industry peers.
  • SLNO has a Return On Invested Capital of 1.48%. This is amongst the best in the industry. SLNO outperforms 88.65% of its industry peers.
Industry RankSector Rank
ROA 3.63%
ROE 4.55%
ROIC 1.48%
ROA(3y)-23.69%
ROA(5y)-49.77%
ROE(3y)-30.65%
ROE(5y)-99.65%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • SLNO has a better Profit Margin (10.75%) than 90.77% of its industry peers.
  • The Operating Margin of SLNO (4.94%) is better than 89.23% of its industry peers.
  • SLNO has a better Gross Margin (98.58%) than 97.88% of its industry peers.
Industry RankSector Rank
OM 4.94%
PM (TTM) 10.75%
GM 98.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), SLNO is destroying value.
  • Compared to 1 year ago, SLNO has more shares outstanding
  • Compared to 5 years ago, SLNO has more shares outstanding
  • Compared to 1 year ago, SLNO has an improved debt to assets ratio.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • SLNO has an Altman-Z score of 10.59. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
  • SLNO has a Altman-Z score of 10.59. This is amongst the best in the industry. SLNO outperforms 82.12% of its industry peers.
  • SLNO has a debt to FCF ratio of 1.07. This is a very positive value and a sign of high solvency as it would only need 1.07 years to pay back of all of its debts.
  • SLNO has a Debt to FCF ratio of 1.07. This is amongst the best in the industry. SLNO outperforms 94.04% of its industry peers.
  • SLNO has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
  • SLNO's Debt to Equity ratio of 0.11 is on the low side compared to the rest of the industry. SLNO is outperformed by 62.69% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for SLNO, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.07
Altman-Z 10.59
ROIC/WACC0.17
WACC8.65%
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • SLNO has a Current Ratio of 5.80. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 5.80, SLNO is in the better half of the industry, outperforming 60.77% of the companies in the same industry.
  • SLNO has a Quick Ratio of 5.55. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 5.55, SLNO is doing good in the industry, outperforming 60.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.8
Quick Ratio 5.55
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • SLNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 105.40%, which is quite impressive.
EPS 1Y (TTM)105.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SLNO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 256.59% yearly.
  • The Revenue is expected to grow by 77.87% on average over the next years. This is a very strong growth
EPS Next Y1768.07%
EPS Next 2Y449.75%
EPS Next 3Y256.59%
EPS Next 5YN/A
Revenue Next Year154.6%
Revenue Next 2Y100.56%
Revenue Next 3Y77.87%
Revenue Next 5YN/A

3.3 Evolution

SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 2028 200M 400M 600M 800M 1B
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 164.00 indicates a quite expensive valuation of SLNO.
  • Based on the Price/Earnings ratio, SLNO is valued cheaply inside the industry as 87.50% of the companies are valued more expensively.
  • SLNO is valuated expensively when we compare the Price/Earnings ratio to 26.83, which is the current average of the S&P500 Index.
  • SLNO is valuated reasonably with a Price/Forward Earnings ratio of 8.78.
  • 97.69% of the companies in the same industry are more expensive than SLNO, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 24.95. SLNO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 164
Fwd PE 8.78
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SLNO is valued cheaply inside the industry as 89.81% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of SLNO indicates a rather cheap valuation: SLNO is cheaper than 93.08% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 41.67
EV/EBITDA 133.44
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • SLNO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as SLNO's earnings are expected to grow with 256.59% in the coming years.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y449.75%
EPS Next 3Y256.59%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (3/3/2026, 8:00:02 PM)

After market: 38.25 +0.53 (+1.41%)

37.72

-1.34 (-3.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners124.99%
Inst Owner Change-1.99%
Ins Owners1.26%
Ins Owner Change4.96%
Market Cap1.95B
Revenue(TTM)190.41M
Net Income(TTM)20.48M
Analysts86.32
Price Target114.16 (202.65%)
Short Float %19.21%
Short Ratio6.32
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)384.69%
Min EPS beat(2)10.35%
Max EPS beat(2)759.03%
EPS beat(4)3
Avg EPS beat(4)212.43%
Min EPS beat(4)-0.42%
Max EPS beat(4)759.03%
EPS beat(8)4
Avg EPS beat(8)75.61%
EPS beat(12)5
Avg EPS beat(12)42.49%
EPS beat(16)8
Avg EPS beat(16)34.88%
Revenue beat(2)2
Avg Revenue beat(2)18.07%
Min Revenue beat(2)1.56%
Max Revenue beat(2)34.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.25%
PT rev (3m)-4.13%
EPS NQ rev (1m)5.32%
EPS NQ rev (3m)14.04%
EPS NY rev (1m)2.93%
EPS NY rev (3m)37.83%
Revenue NQ rev (1m)5.11%
Revenue NQ rev (3m)7.31%
Revenue NY rev (1m)1.27%
Revenue NY rev (3m)19.66%
Valuation
Industry RankSector Rank
PE 164
Fwd PE 8.78
P/S 10.23
P/FCF 41.67
P/OCF 41.61
P/B 4.33
P/tB 4.37
EV/EBITDA 133.44
EPS(TTM)0.23
EY0.61%
EPS(NY)4.3
Fwd EY11.39%
FCF(TTM)0.91
FCFY2.4%
OCF(TTM)0.91
OCFY2.4%
SpS3.69
BVpS8.72
TBVpS8.63
PEG (NY)0.09
PEG (5Y)N/A
Graham Number6.72
Profitability
Industry RankSector Rank
ROA 3.63%
ROE 4.55%
ROCE 1.87%
ROIC 1.48%
ROICexc 3.78%
ROICexgc 3.87%
OM 4.94%
PM (TTM) 10.75%
GM 98.58%
FCFM 24.54%
ROA(3y)-23.69%
ROA(5y)-49.77%
ROE(3y)-30.65%
ROE(5y)-99.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.07
Debt/EBITDA 4.36
Cap/Depr 3.62%
Cap/Sales 0.04%
Interest Coverage 2.08
Cash Conversion 409.4%
Profit Quality 228.21%
Current Ratio 5.8
Quick Ratio 5.55
Altman-Z 10.59
F-Score7
WACC8.65%
ROIC/WACC0.17
Cap/Depr(3y)4.86%
Cap/Depr(5y)3.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%162.99%
EPS Next Y1768.07%
EPS Next 2Y449.75%
EPS Next 3Y256.59%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year154.6%
Revenue Next 2Y100.56%
Revenue Next 3Y77.87%
Revenue Next 5YN/A
EBIT growth 1Y105.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3691%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y167.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y167.73%
OCF growth 3YN/A
OCF growth 5YN/A

SOLENO THERAPEUTICS INC / SLNO FAQ

What is the ChartMill fundamental rating of SOLENO THERAPEUTICS INC (SLNO) stock?

ChartMill assigns a fundamental rating of 6 / 10 to SLNO.


Can you provide the valuation status for SOLENO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 7 / 10 to SOLENO THERAPEUTICS INC (SLNO). This can be considered as Undervalued.


How profitable is SOLENO THERAPEUTICS INC (SLNO) stock?

SOLENO THERAPEUTICS INC (SLNO) has a profitability rating of 5 / 10.


Can you provide the PE and PB ratios for SLNO stock?

The Price/Earnings (PE) ratio for SOLENO THERAPEUTICS INC (SLNO) is 164 and the Price/Book (PB) ratio is 4.33.


Can you provide the financial health for SLNO stock?

The financial health rating of SOLENO THERAPEUTICS INC (SLNO) is 8 / 10.